CD274 and cancer: Phase 1 and 2 trials are currently open to prospectively assess a positive effect of concurrent metformin on anti-PD-1 and anti-PD-L1 treatment for different types of cancer: melanoma (NCT04114136), NSCLC (NCT03048500), or microsatellite stable (MSS) colorectal cancer (NCT03800602) [97,106,107].